![Amicus Therapeutics](https://s33007.pcdn.co/wp-content/uploads/2020/07/Amicus-Therapeutics-Inc.jpg)
Amicus is a global patient-focused biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (“ERT”) for Fabry disease.